‘Axelyf Appoints Daniel Frímannsson, Ph.D., Head of Nucleic Acid Technologies & Biology and Leslie Williams to Board’

December 16, 2025

Axelyf announced the appointment of two experienced biotech leaders to further strengthen its RNA therapeutics strategy. Daniel (Danni) Frímannsson, Ph.D., joins the company as head of nucleic acid technologies and biology, bringing extensive expertise in RNA drug development, LNP formulation, and CMC from roles at Mammoth Biosciences and Nutcracker Therapeutics. Leslie Williams, a veteran biotechnology executive with more than 25 years of leadership experience, has been appointed to Axelyf’s Board of Directors. These appointments support Axelyf’s continued advancement of its LNP platform and internal RNA programs as the company moves toward key preclinical milestones.

The full press release was published by EIN Presswire.